Treatment
Interruption (TI)
Mechanisms
for Elevated Risk of Cardiovascular Disease and Death in SMART and STACCATO Treatment
Interruption Trials -
2/08/08
New
Studies Reveal Detrimental Effects of
Treatment interruption -
2/01/08
Impact
of Episodic CD4-guided Treatment
Interruption
on Quality of Life -
1/29/08
Predictors
of Loss of Virological Control in Patients Receiving Lopinavir/ritonavir (Kaletra)
Monotherapy - 3/20/07
Cardiovascular
Risk Factors, Lipoatrophy, and Lipid Profiles in SMART Study -
3/06/07
HIV
Transmission in SMART Study - 3/06/07
Guided
Treatment Interruptions Are Not as Safe as Continuing Therapy 1/19/07
Treatment
Interruption before Optimized Antiretroviral Therapy 12/08/06
Treatment
Interruption Linked to Increased Risk of HIV Rebound
12/01/06
SMART
Data Confirm Risk of CD4-guided Treatment Interruptions
12/08/06
CD4-guided
Treatment Interruptions vs Continuous Antiretroviral Therapy in Staccato
Trial -
9/01/06
Reasons for Adverse SMART Outcomes Remain Poorly Understood
- 8/15/06
Do
IL-2 and Hydroxyurea Facilitate Structured Treatment Interruption?
-
6/23/06
Lamivudine
Monotherapy May Lead to a Better Immunologic and Clinical Outcome Than Complete
Treatment Interruption in HIV Patients with Lamivudine-resistant Virus
-
3/31/06
Long-cycle
Structured Treatment Interruption Does Not Improve Health-related Quality
of Life or Symptom Distress when Compared to Continuous HAART -
3/31/06
Trials
of Strategic Treatment Interruptions in the Management of HIV Infection
- 3/07/06
Large
International Trial Finds Continuous Anti-HIV Therapy Is Greatly Superior to Treatment
Interruptions: The SMART Study - 1/20/06
Questions
and Answers about the SMART Study - 1/20/06 | 
